Put companies on watchlist
CompuGroup Medical SE & Co. KGaA
ISIN: DE000A288904
WKN: A28890
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

CompuGroup Medical SE & Co. KGaA · ISIN: DE000A288904 · EQS - Company News (90 News)
Country: Germany · Primary market: Germany · EQS NID: 1768965
09 November 2023 07:07AM

CGM continues to drive digitization in healthcare and reports 10 % revenue growth in first nine months


EQS-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Quarter Results/9 Month figures
CGM continues to drive digitization in healthcare and reports 10 % revenue growth in first nine months

09.11.2023 / 07:07 CET/CEST
The issuer is solely responsible for the content of this announcement.


CGM continues to drive digitization in healthcare and reports 10 % revenue growth in first nine months

 

  • CGM supports ramp-up in usage of digital modules to improve the patient journey
  • Increasing momentum in projects relating to Hospital Future Act
  • Growing relevance of data & AI based solutions
  • 8 % organic growth with 68 % recurring revenues
  • Full year guidance confirmed based on profitable year-to-date growth

 

Koblenz. CompuGroup Medical SE & Co. KGaA (CGM), one of the world's leading e-health providers, successfully progressed the digitization in healthcare during the first three quarters in 2023. CGM supports physicians to enable a fully digital patient journey by providing additional modules to process emergency data sets, electronic medication plan and handling e-health records. Together with the gematik, CGM has supported its customers – doctors, hospitals and pharmacies – in the third quarter to drive the usage of e-Prescriptions for the benefit of patients. And the joint efforts of gematik, CGM and others have created traction: According to gematik, the number of medical institutions issuing e-Prescriptions in Germany per week has more than doubled in the past months to now more than 14 thousand, while the number of redeemed e-Prescriptions has also more than doubled to more than 6.5 million.

Digitization is also gaining momentum in German hospitals. CGM registered a further ramp-up of projects related to the Hospital Future Act for several consecutive quarters. The German governmental initiative for the modernization and digitization of hospitals is a key growth driver in CGM's hospital information systems segment. Also, CGM is increasingly providing clinical rehab customers with connectivity solutions, thereby laying the foundation for further digitization measures.

In addition CGM is planning to further support physicians with the usage of intelligence data tools and driving in-house efficiency by the use of AI-tools. The AI initiative announced in summer to boost the use of artificial intelligence in products and business processes will increase efficiency going forward. The in-house AI tool, based on Azure OpenAI ChatGPT, is now available to all CGM employees, is being used widely across the group. Accordingly, the integration of AI mechanisms into CGM's processes continues.

“We have made further progress in the third quarter in driving digitization in healthcare, especially in Germany. CGM is supporting physicians, hospitals and pharmacies in their daily challenge of coping with limited time per patient and exploding medical knowledge. Data-driven and AI-based solutions are going to change healthcare, and CGM is at the forefront of the development. Using AI will also allow us to grow more efficiently going forward.”, explains Michael Rauch CEO of CompuGroup Medical.

The successful business development is reflected in the financials of the first three quarters in 2023. Group revenues grew by 10 percent year-on-year to EUR 881 million. The quality of revenues, reflected in a recurring revenue share of 68 percent, underlines the strength of CGM's business model. Adjusted EBITDA grew by 18 percent, and free cash flow reached EUR 90 million in the first nine months of the year. With an organic growth of 8 percent compared to the prior year period, CGM is well on track towards the full year ambition and thus confirms its guidance for the financial year 2023.

CGM also strengthened the financing situation in the third quarter by prolonging and extending the available funding considerably. CGM successfully debuted on the international debt capital market in October by issuing Schuldschein volume of EUR 300 million at attractive conditions and with extended maturities. Given the strong earnings and free cash flow profile, the focus is now on deleveraging while at the same time allowing for strategic add-on acquisitions.

 

Financial key figures

EUR million  Q3 2023  Q3 2022  Change  01.01.-30.09.2023  01.01.-30.09.2022  Change 
Revenues  285.7  285.4  + 0 %  880.7  802.1  + 10 % 
Recurring revenues in %  71 %  65 %  + 6 ppt  68 %  68 %  + 0 ppt 
Organic growth in %  1.5 %  -3 %  + 4 ppt  8 %  2 %  + 6 ppt 
EBITDA adjusted  62.1  61.0  + 2 %  195.2  166.1  + 18 % 
EBITDA margin adjusted  22 %  21 %  + 1 ppt  22 %  21 %  + 1 ppt 
EPS adjusted (EUR) - diluted  0.43  0.51  - 16 %  1.50  1.33  + 13 % 
Free cash flow  7.6  - 4.6  + 270 %  90.3  23.6  + 283 % 
Number of shares outstanding (‘000)        52,235  52,235  + 0 % 

 
About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.13 billion in 2022, its software products are designed to support all medical and

organizational activities in doctors’ offices, pharmacies, laboratories, hospitals, and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical’s services are based on a unique customer base of more than 1.6 million users, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities. With locations in 21 countries and products in 60 countries worldwide, CompuGroup Medical is the e-health company with one of the highest coverages among healthcare professionals. More than 9,200 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system



09.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
E-mail: investor@cgm.com
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1768965

 
End of News EQS News Service

1768965  09.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1768965&application_name=news&site_id=boersengefluester_html
Visual performance / price development - CompuGroup Medical SE & Co. KGaA
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.